SB-742457 And Donepezil In Alzheimer's Disease
Alzheimer's Disease
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's Disease, cognition global functioning, symptomatic, SB-742457
Eligibility Criteria
Inclusion criteria: Clinical diagnosis of probable mild-to-moderate Alzheimer's Disease as determined by the NINCDS-ADRDA and DSM-IV criteria with an MMSE score of 12-24. Subjects and their caregivers must provide informed consent prior to study entry. Adequate blood pressure and laboratory values. Exclusion criteria: Females of child-bearing potential. Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency. Subjects taking medication for Alzheimers disease or centrally acting agents which might impact study outcomes. Subjects taking agents for which there is a theoretical risk of interaction with SB-742457 or donepezil. Subjects with conditions which might be exacerbated by exposure to donepezil. Subjects with known hypersensitivity to sunlight or seizures.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site